RecruitingPhase 2NCT06421636
A Study to Test the Safety, Tolerability, and Efficacy of an Antibody, REGN7999, Injected Under the Skin for the Treatment of Iron Overload in Adult Participants With Non-Transfusion Dependent β-thalassemia, Using MRI Scans to Measure Iron Levels in the Body
Studying Beta-thalassemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Regeneron Pharmaceuticals
- Principal Investigator
- Clinical Trial ManagementRegeneron Pharmaceuticals
- Intervention
- REGN7999(drug)
- Enrollment
- 95 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2028
Study locations (26)
- Weill Cornell Medicine, New York, New York, United States
- K Eristavi National Center of Experimental and Clinical Surgery, Tbilisi, Georgia
- Medinvest Institute of Hematology and Transfusiology Limited, Tbilisi, Georgia
- Children's Hospital Agia Sophia, Athens, Attica, Greece
- Laiko General Hospital of Athens, Athens, Attica, Greece
- University Hospital of Ioannina, Ioannina, Greece
- Hemato-Oncology Clinic Ahmedabad PVT. LTD., Ahmedabad, Gujarat, India
- Nirmal Hospital Pvt. Ltd - Surat, Surat, Gujarat, India
- Amrita Institute of Medical Sciences and Research Centre (AIMS), Kochi, Kerala, India
- K J Somaiya Super Specialty Hospital & Research Centre, Mumbai, Maharashtra, India
- All India Institute of Medical Sciences, New Delhi, New Delhi, National Capital Territory of Delhi, India
- Indraprastha Apollo Hospitals, New Delhi, National Capital Territory of Delhi, India
- JK Lon Hospital, Jaipur, Rajasthan, India
- Day Hospital Thalassemia and Haemoglobinopathies (DHTE); A.O.U S.Anna, Ferrara, Italy
- Hospital Queen Elizabeth, Kota Kinabalu, Sabah, Malaysia
- +11 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06421636 on ClinicalTrials.govOther trials for Beta-thalassemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07215975A Real-World Study to Evaluate Luspatercept in Adults With Transfusion-Dependent Beta-Thalassemia in the Middle EastBristol-Myers Squibb
- ENROLLING BY INVITATIONNCT07055503Use of the Hemanext One® Hypoxic Red Blood Cell Storage System for Transfusion in Thalassemia PatientsUniversity Research Institute for the Study of Genetic & Malignant Disorders in Childhood
- RECRUITINGNANCT07207577Evaluation of Physiological and Psychological Factors Involved in Exercise Intolerance in Patients With β-TTDCentre Hospitalier Metropole Savoie
- ENROLLING BY INVITATIONNCT06717932A Follow-up Study to Evaluate the Long-term Safety and Efficacy in Participants Who Received CS-101 InjectionCorrectSequence Therapeutics Co., Ltd
- RECRUITINGPHASE1, PHASE2NCT06364774ALS20-101 Lentiviral Gene Therapy for Beta ThalassemiaChildren's Hospital of Philadelphia
- ENROLLING BY INVITATIONNCT06685536A Long-term Follow-up Study in Participants Who Received CS-101CorrectSequence Therapeutics Co., Ltd
- RECRUITINGPHASE1NCT06772766A Multiple Ascending Dose Study of 9MW3011 in Patients With Non-transfusion-dependent β-thalassemiaMabwell (Shanghai) Bioscience Co., Ltd.
- RECRUITINGNANCT06734520Clinical Study of Super Transplantation in the Treatment of Severe β-thalassemiaGuangzhou Women and Children's Medical Center